Akanda (AKAN) Competitors $1.29 +0.03 (+2.37%) Closing price 05/2/2025 03:58 PM EasternExtended Trading$1.34 +0.05 (+3.88%) As of 05/2/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. SNOA, CPHI, GTBP, AEZS, FRTX, NLSP, SNGX, ONCO, APM, and ENSCShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), GT Biopharma (GTBP), Aeterna Zentaris (AEZS), Fresh Tracks Therapeutics (FRTX), NLS Pharmaceutics (NLSP), Soligenix (SNGX), Onconetix (ONCO), Aptorum Group (APM), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Sonoma Pharmaceuticals China Pharma GT Biopharma Aeterna Zentaris Fresh Tracks Therapeutics NLS Pharmaceutics Soligenix Onconetix Aptorum Group Ensysce Biosciences Sonoma Pharmaceuticals (NASDAQ:SNOA) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Which has more risk & volatility, SNOA or AKAN? Sonoma Pharmaceuticals has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Akanda has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Does the MarketBeat Community prefer SNOA or AKAN? Sonoma Pharmaceuticals received 216 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformSonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% AkandaN/AN/A Is SNOA or AKAN more profitable? Akanda has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Akanda's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-26.82% -68.98% -26.39% Akanda N/A N/A N/A Which has stronger valuation and earnings, SNOA or AKAN? Sonoma Pharmaceuticals has higher revenue and earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$13.97M0.39-$4.84M-$4.02-0.84Akanda$2.51M0.73-$32.28MN/AN/A Does the media favor SNOA or AKAN? In the previous week, Akanda had 3 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 3 mentions for Akanda and 0 mentions for Sonoma Pharmaceuticals. Akanda's average media sentiment score of 0.17 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Akanda is being referred to more favorably in the news media. Company Overall Sentiment Sonoma Pharmaceuticals Neutral Akanda Neutral Do insiders & institutionals hold more shares of SNOA or AKAN? 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAkanda beats Sonoma Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84M$1.16B$5.55B$8.03BDividend YieldN/AN/A5.09%4.23%P/E RatioN/A9.7722.6918.84Price / Sales0.739.91404.96106.72Price / CashN/A10.4038.1834.62Price / Book-0.021.506.794.33Net Income-$32.28M-$54.34M$3.22B$247.97M7 Day Performance12.17%2.84%3.34%3.17%1 Month Performance-3.01%34.86%6.89%8.24%1 Year Performance-82.18%-33.60%16.04%4.98% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.29+2.4%N/A-83.4%$1.84M$2.51M0.00110News CoverageSNOASonoma Pharmaceuticals0.887 of 5 stars$3.94-6.9%N/A+2,107.7%$6.37M$13.97M-0.98180CPHIChina PharmaN/A$1.93+3.4%N/A-93.7%$6.31M$4.53M0.00250GTBPGT Biopharma3.4717 of 5 stars$2.30+0.9%$11.00+378.3%-27.1%$5.96MN/A-0.338Short Interest ↓Positive NewsGap DownAEZSAeterna ZentarisN/A$3.22+2.2%N/A-53.4%$5.77M$2.37M-0.2220Analyst ForecastNews CoverageFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+2.7%$5.59M$10.06M-0.6620NLSPNLS PharmaceuticsN/A$1.47-2.0%N/A+1,069.3%$5.29MN/A0.006SNGXSoligenix0.2506 of 5 stars$2.06-5.1%N/A-70.6%$5.17M$840,000.00-0.2720Upcoming EarningsONCOOnconetix1.3264 of 5 stars$0.08+14.4%N/A-98.5%$5.16M$1.87M0.0012Gap UpHigh Trading VolumeAPMAptorum Group0.7143 of 5 stars$0.98+1.0%N/A-82.8%$5.08M$430,000.000.0030ENSCEnsysce Biosciences0.0797 of 5 stars$2.93-10.9%N/A-69.9%$4.82M$2.23M-0.1110Upcoming Earnings Related Companies and Tools Related Companies SNOA Competitors CPHI Competitors GTBP Competitors AEZS Competitors FRTX Competitors NLSP Competitors SNGX Competitors ONCO Competitors APM Competitors ENSC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKAN Stock Free AKAN Stock Alerts